A Randomized, Open-label, Multicenter, Two-arm, Phase III Study to Evaluate Efficacy and Quality of Life in Postmenopausal Patients With Metastatic HR-positive HER2-negative Breast Cancer Receiving Ribociclib in Combination With Aromatase Inhibitor or Paclitaxel With or Without Bevacizumab in First Line

Trial Profile

A Randomized, Open-label, Multicenter, Two-arm, Phase III Study to Evaluate Efficacy and Quality of Life in Postmenopausal Patients With Metastatic HR-positive HER2-negative Breast Cancer Receiving Ribociclib in Combination With Aromatase Inhibitor or Paclitaxel With or Without Bevacizumab in First Line

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs Aromatase inhibitors (Primary) ; Ribociclib (Primary) ; Bevacizumab; Paclitaxel
  • Indications Adenocarcinoma; Breast cancer; Postmenopause
  • Focus Therapeutic Use
  • Acronyms RIBBIT
  • Sponsors iOMEDICO AG
  • Most Recent Events

    • 14 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top